<DOC>
	<DOCNO>NCT01558089</DOCNO>
	<brief_summary>This open-label , prospective , observational study evaluate clinical response etanercept + methotrexate therapy patient moderate severe rheumatoid arthritis , prescribed rheumatologist normal clinical setting Greece</brief_summary>
	<brief_title>Good EULAR Response In Patients With Early Rheumatoid Arthritis</brief_title>
	<detailed_description>All subject enrol meet usual prescribe criterion Etanercept per local product information enter study investigator 's discretion</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1. sign date informed consent document 2 . 18 year age old time consent 3 . Patients moderatetosevere active rheumatoid arthritis , satisfy 2010 Rheumatoid Arthritis Classification Criteria 4 . Patients prescribe first time receive treatment MTX + Etanercept prior enrollment study , follow routine clinical practice accord approve SmPC , 5 . Patients DAS28 ≥ 3.2 6 . Duration disease symptom ≥ 6 week ≤2 year 7 . Failure respond prior DMARDs include MTX monotherapy accord routine clinical practice . 1 . Contraindications accord SmPC 2 . History present antiTNFa biologic therapy treatment RA 3 . Known significant concurrent medical disease accord investigator 's opinion current SmPC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>